Uncategorized
Genentech reacts to DRCR.net Protocol T data
In a company-issued statement, Genentech responds to data regarding the DRCR.net Protocol T:Genentech thanks the Diabetic Retinopathy Clinical Research Network (DRCR.net) for bringing this important data to patients and physicians.The preliminary 1-year results of the DRCR.net Protocol T trial reinforce the safety and efficacy of Lucentis for diabetic macular edema (DME). The trial studied Lucentis 0.3 mg given less than monthly compared with other anti-VEGF agents in DME.